Small molecule (Molecular glue degrader) · Degrader of RAS (wild-type and mutant forms, GTP-bound state) (KRAS) · developed by Erasca
ERAS-0015 is an orally bioavailable pan-RAS molecular glue that binds RAS in its GTP-bound active state together with cyclophilin A, forming a ternary complex that inhibits signaling by wild-type and mutant RAS. It is being studied in metastatic solid tumors, alone and in combination with pembrolizumab or panitumumab.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06983743 | Phase 1 | Metastatic Solid Tumors | Recruiting | ERAS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Solid Tumors
Updated Oct 11, 2026. Something wrong or missing? Report it on the ERAS page.
See ERAS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ERAS catalysts and pipeline →